Search hospitals > California > San Francisco

California Pacific Medical Center

Claim this profile
San Francisco, California 94115
Global Leader in HIV Infection
Global Leader in Human Immunodeficiency Virus Infection
Conducts research for Amyotrophic Lateral Sclerosis
Conducts research for AIDS
Conducts research for Pancreatic Cancer
228 reported clinical trials
9 medical researchers
Photo of California Pacific Medical Center in San FranciscoPhoto of California Pacific Medical Center in San FranciscoPhoto of California Pacific Medical Center in San Francisco

Summary

California Pacific Medical Center is a medical facility located in San Francisco, California. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, Amyotrophic Lateral Sclerosis, AIDS, Pancreatic Cancer and other specialties. California Pacific Medical Center is involved with conducting 228 clinical trials across 262 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christian Spies, MD, Jonathan Katz, MD, and Stewart Cooper, Dr..

Top PIs

Clinical Trials running at California Pacific Medical Center

Ovarian Cancer

Endometrial Cancer

Stroke

Amyotrophic Lateral Sclerosis

Non-Small Cell Lung Cancer

Breast Cancer

Prostate Cancer

Head and Neck Cancers

Colorectal Cancer

Spinal Muscular Atrophy

Image of trial facility.

PARG Inhibitor

for Advanced Cancers

This trial is testing a new drug called IDE161 to see if it is safe and effective for patients with advanced cancers that have specific genetic changes. The drug works by preventing cancer cells from repairing their DNA, which can lead to their death.

Recruiting

1 award

Phase 1

4 criteria

Image of trial facility.

Carboplatin + Mirvetuximab Soravtansine

for Ovarian Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States. Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years . There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

Recruiting

1 award

Phase 2

4 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at California Pacific Medical Center?

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.

Terms of Service·Privacy Policy·Cookies·Security